alexa Editor - William Douglas Figg | The Center for Cancer Research | 11077
ISSN: 2157-7412

Journal of Genetic Syndromes & Gene Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
  • 5th International Conference on Human Genetics and Genetic Disorders September 21-22,2018 Philadelphia, USA Theme: Sharing Discoveries of the Future Human Genome
    September 21-22,2018 Philadelphia, USA
View More»
 

William Douglas Figg

William Douglas Figg William Douglas Figg
Senior Investigator
The Center for Cancer Research
National Cancer Institute/National Institutes of Health
Bethesda  
Biography

Dr. Figg received his B.S. in pharmacy from Samford University and his doctorate in pharmacy (Pharm.D.) from Auburn University. He also has a dual MBA degree from Columbia University and London Business School. Following his clinical internship at the University of Alabama at Birmingham and his fellowship training at the University of North Carolina at Chapel Hill, he joined the Clinical Pharmacology Branch of the NCI. Dr. Figg became chief of the Molecular and Clinical Pharmacology Section in 1993. More recently, this section was divided into two groups, the Molecular Pharmacology Section within the Medical Oncology Branch and the Clinical Pharmacology Program within the Office of Clinical Director, CCR, NCI. The Clinical Pharmacology Program has 5 cores - the Blood Processing Core, Bioanalytical Core, Preclinical Pharmacokinetics Core, Pharmacometrics Core and Pharmacogenetics Core. Dr. Figg has focused his research on utilizing pharmacological principles in anticancer drug development and evaluating novel agents in the treatment of cancer. Dr. Figg serves on the Molecular Target Faculty Steering Committee, the Technology Review Group, the NExT Committee, the NIHCC Pharmacogenetics Committee, and chairs the steering committee of the Molecular Targets Development Program. Dr. Figg is also a member of the GU Center of Excellence steering committee. He is on the editorial board of 18 peer-reviewed scientific journals (e.g., Clinical Cancer Research, Cancer Biology & Therapy, Clinical Pharmacology and Therapeutics, The Oncologist, Cancer Chemotherapy and Pharmacology, Molecular Cancer Therapeutics, and Pharmacotherapy). He has been licensed to practice pharmacy since 1988 and in 1991, he became board certified in Pharmacotherapy (recertified in 2007). He holds adjunct appointments at four schools of pharmacy - Samford University, Virginia Commonwealth University, University of Michigan and the University of Maryland. Dr. Figg is also an Adjunct Professor at Columbia University College of Physicians and Surgeons. He has trained Ph.D. graduate students from Oxford University, Johns Hopkins, University of Pittsburgh, University of Maryland and George Washington. Dr. Figg is also a fellow in the American College of Clinical Pharmacy and a fellow in the American College of Clinical Pharmacology. He was named the Allen J. Brands Clinical Pharmacist of the Year in 2001, the Association of Military Surgeons of the United States in 2003 gave him the Clinical Pharmacist of the Year award, and he received the 2005 Leon Goldberg Young Investigator Award from the American Society of Clinical Pharmacology and Therapeutics. In addition, he received the 2008 Russell R. Miller Award and the 2008 ASHP Award for Sustained Contribution to the Scientific Literature. In 2009 he received the AMSUS Andrew Craigie Award for Outstanding Advancement of the Profession of Pharmacy. In 2011 he gave the Philip C. and Ethel F. Ashby Lecture at the University of Oklahoma. Dr. Figg has over 500 peer-reviewed publications, has patented over 80 novel anticancer agents and devices and given over 150 invited scientific presentations/lectures throughout the world.

Research Interest

Pharmacology and Experimental Therapeutics

Certificate
Certificate

Global Speakers in the subject

Global Experts in the subject

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]micsonline.com

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7